Mobile website
Review
Role of CD44v6 in the pathological progression of myelodysplastic syndromes and advances in targeted therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Myelodysplastic syndromes (MDS) are a group of myeloid malignancies originating from hematopoietic stem cells, with an increasing incidence rate year by year. In recent years, chimeric antigen receptor gene-modified T lymphocyte (CAR-T cell) therapy targeting specific antigens has achieved remarkable success in the field of hematological tumors, opening up new directions for the treatment of MDS. The key to promoting the successful application of CAR-T cell therapy lies in finding MDS-specific target antigens. Studies have found that CD44 splice variant CD44v6 is generally highly expressed in early-stage ineffective erythropoiesis in MDS patients, suggesting it is a highly promising therapeutic target. This review systematically summarizes the new research progress on CD44v6 regulating the pathological process of MDS, focuses on analyzing the clinical translational value of innovative therapeutic strategies targeting CD44v6 (including CAR-T cell therapy), and explores its application prospects in promoting precision personalized treatment of MDS.
Keywords:
Project Supported:
Clc Number:
